Click here to get full coverage on BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposiu - GuruFocus

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposiu  GuruFocus

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposiu - GuruFocus

Click here to get full coverage on BriaCell (NASDAQ: BCTX) and Receptor.AI launch AI-driven kinase inhibitor collaboration - Stock Titan

BriaCell (NASDAQ: BCTX) and Receptor.AI launch AI-driven kinase inhibitor collaboration  Stock Titan

BriaCell (NASDAQ: BCTX) and Receptor.AI launch AI-driven kinase inhibitor collaboration - Stock Titan

Click here to get full coverage on All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on Aug Momentum: Why BCTX stock remains undervalued - Earnings Overview Summary & High Accuracy Trade Signal Alerts - moha.gov.vn

Aug Momentum: Why BCTX stock remains undervalued - Earnings Overview Summary & High Accuracy Trade Signal Alerts  moha.gov.vn

Aug Momentum: Why BCTX stock remains undervalued - Earnings Overview Summary & High Accuracy Trade Signal Alerts - moha.gov.vn

Click here to get full coverage on BCTX Stock Surges Amid Positive Developments and Strategic Moves - StocksToTrade

BCTX Stock Surges Amid Positive Developments and Strategic Moves  StocksToTrade

BCTX Stock Surges Amid Positive Developments and Strategic Moves - StocksToTrade

Click here to get full coverage on New Analyst Forecast: $BCTX Given $40.0 Price Target | BCTX Stock News - Quiver Quantitative

New Analyst Forecast: $BCTX Given $40.0 Price Target | BCTX Stock News  Quiver Quantitative

New Analyst Forecast: $BCTX Given $40.0 Price Target | BCTX Stock News - Quiver Quantitative

Click here to get full coverage on BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire

BriaCell Announces Proposed Effective Date of Share Consolidation  GlobeNewswire

BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire

Click here to get full coverage on BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Brea - GuruFocus

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Brea  GuruFocus

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Brea - GuruFocus

Click here to get full coverage on BriaCell Therapeutics (NASDAQ: BCTX) Highlights Metastatic Breast Cancer Phase 2/3 Data - Stock Titan

BriaCell Therapeutics (NASDAQ: BCTX) Highlights Metastatic Breast Cancer Phase 2/3 Data  Stock Titan

BriaCell Therapeutics (NASDAQ: BCTX) Highlights Metastatic Breast Cancer Phase 2/3 Data - Stock Titan

Click here to get full coverage on BriaCell (NASDAQ: BCTX) joins MSK Accelerator to support Bria-BRES+ Phase 1 in breast cancer - Stock Titan

BriaCell (NASDAQ: BCTX) joins MSK Accelerator to support Bria-BRES+ Phase 1 in breast cancer  Stock Titan

BriaCell (NASDAQ: BCTX) joins MSK Accelerator to support Bria-BRES+ Phase 1 in breast cancer - Stock Titan

Click here to get full coverage on BriaCell (NASDAQ: BCTX) to Share Phase 2 & 3 Metastatic Breast Cancer Posters at SABCS - Stock Titan

BriaCell (NASDAQ: BCTX) to Share Phase 2 & 3 Metastatic Breast Cancer Posters at SABCS  Stock Titan

BriaCell (NASDAQ: BCTX) to Share Phase 2 & 3 Metastatic Breast Cancer Posters at SABCS - Stock Titan

Click here to get full coverage on BriaCell (NASDAQ: BCTX) receives 4th DSMB recommendation for Phase 3 breast cancer study - Stock Titan

BriaCell (NASDAQ: BCTX) receives 4th DSMB recommendation for Phase 3 breast cancer study  Stock Titan

BriaCell (NASDAQ: BCTX) receives 4th DSMB recommendation for Phase 3 breast cancer study - Stock Titan

Click here to get full coverage on BriaCell (NASDAQ: BCTX) adds Dartmouth, Cedars-Sinai, Emory; 79 sites in Phase 3 - Stock Titan

BriaCell (NASDAQ: BCTX) adds Dartmouth, Cedars-Sinai, Emory; 79 sites in Phase 3  Stock Titan

BriaCell (NASDAQ: BCTX) adds Dartmouth, Cedars-Sinai, Emory; 79 sites in Phase 3 - Stock Titan

Click here to get full coverage on BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan

BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know  Stock Titan

BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan

Click here to get full coverage on BriaCell (NASDAQ: BCTX) to present SITC data on Bria-OTS+; $2M NCI award backs Bria-PROS+ - Stock Titan

BriaCell (NASDAQ: BCTX) to present SITC data on Bria-OTS+; $2M NCI award backs Bria-PROS+  Stock Titan

BriaCell (NASDAQ: BCTX) to present SITC data on Bria-OTS+; $2M NCI award backs Bria-PROS+ - Stock Titan

Click here to get full coverage on BriaCell (NASDAQ: BCTX) presents preclinical immune activation data for Bria-OTS+ at SITC 2025 - Stock Titan

BriaCell (NASDAQ: BCTX) presents preclinical immune activation data for Bria-OTS+ at SITC 2025  Stock Titan

BriaCell (NASDAQ: BCTX) presents preclinical immune activation data for Bria-OTS+ at SITC 2025 - Stock Titan

Click here to get full coverage on BriaCell (Nasdaq: BCTX) shares survival, biomarker data; Phase 3 interim readout 1H2026 - Stock Titan

BriaCell (Nasdaq: BCTX) shares survival, biomarker data; Phase 3 interim readout 1H2026  Stock Titan

BriaCell (Nasdaq: BCTX) shares survival, biomarker data; Phase 3 interim readout 1H2026 - Stock Titan

Click here to get full coverage on Memorial Sloan Kettering Selects BriaCell's Novel Cancer Immunotherapy for 2025 Development Program - Stock Titan

Memorial Sloan Kettering Selects BriaCell's Novel Cancer Immunotherapy for 2025 Development Program  Stock Titan

Memorial Sloan Kettering Selects BriaCell's Novel Cancer Immunotherapy for 2025 Development Program - Stock Titan

Click here to get full coverage on BriaCell to Reveal Pivotal Phase III Breast Cancer Trial Results at Major ESMO Conference - Stock Titan

BriaCell to Reveal Pivotal Phase III Breast Cancer Trial Results at Major ESMO Conference  Stock Titan

BriaCell to Reveal Pivotal Phase III Breast Cancer Trial Results at Major ESMO Conference - Stock Titan

Click here to get full coverage on Cancer Immunotherapy Developer BriaCell Secures $15M Funding: What the Deal Means for Investors - Stock Titan

Cancer Immunotherapy Developer BriaCell Secures $15M Funding: What the Deal Means for Investors  Stock Titan

Cancer Immunotherapy Developer BriaCell Secures $15M Funding: What the Deal Means for Investors - Stock Titan

Click here to get full coverage on BriaCell Secures $15M Funding Boost for Cancer Immunotherapy Development at $1.25 Per Unit - Stock Titan

BriaCell Secures $15M Funding Boost for Cancer Immunotherapy Development at $1.25 Per Unit  Stock Titan

BriaCell Secures $15M Funding Boost for Cancer Immunotherapy Development at $1.25 Per Unit - Stock Titan

Click here to get full coverage on SITC 40th Anniversary: Bria-OTS+ Preclinical Poster — BriaCell to Present Nov 7, 2025 - Stock Titan

SITC 40th Anniversary: Bria-OTS+ Preclinical Poster — BriaCell to Present Nov 7, 2025  Stock Titan

SITC 40th Anniversary: Bria-OTS+ Preclinical Poster — BriaCell to Present Nov 7, 2025 - Stock Titan

Click here to get full coverage on FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan

FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial  Stock Titan

FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan

Click here to get full coverage on BriaCell (BCTX) Announces $15M Public Offering of Common Shares and Warrants | BCTX Stock News - GuruFocus

BriaCell (BCTX) Announces $15M Public Offering of Common Shares and Warrants | BCTX Stock News  GuruFocus

BriaCell (BCTX) Announces $15M Public Offering of Common Shares and Warrants | BCTX Stock News - GuruFocus

Click here to get full coverage on Major Breakthrough: FDA Fast-Track Breast Cancer Treatment Passes Critical Safety Review - Stock Titan

Major Breakthrough: FDA Fast-Track Breast Cancer Treatment Passes Critical Safety Review  Stock Titan

Major Breakthrough: FDA Fast-Track Breast Cancer Treatment Passes Critical Safety Review - Stock Titan

Click here to get full coverage on H.C. Wainwright Maintains BriaCell Therapeutics(BCTX.US) With Buy Rating, Cuts Target Price to $40 - 富途牛牛

H.C. Wainwright Maintains BriaCell Therapeutics(BCTX.US) With Buy Rating, Cuts Target Price to $40  富途牛牛

H.C. Wainwright Maintains BriaCell Therapeutics(BCTX.US) With Buy Rating, Cuts Target Price to $40 - 富途牛牛

Click here to get full coverage on Breakthrough: Complete Brain Tumor Resolution in Patient Who Failed 8 Prior Cancer Treatments - Stock Titan

Breakthrough: Complete Brain Tumor Resolution in Patient Who Failed 8 Prior Cancer Treatments  Stock Titan

Breakthrough: Complete Brain Tumor Resolution in Patient Who Failed 8 Prior Cancer Treatments - Stock Titan

Click here to get full coverage on BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 S - GuruFocus

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 S  GuruFocus

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 S - GuruFocus

Click here to get full coverage on Breakthrough Cancer Treatment Mechanism: BriaCell and NCI Validate Novel Immunotherapy Platform in Major Study - Stock Titan

Breakthrough Cancer Treatment Mechanism: BriaCell and NCI Validate Novel Immunotherapy Platform in Major Study  Stock Titan

Breakthrough Cancer Treatment Mechanism: BriaCell and NCI Validate Novel Immunotherapy Platform in Major Study - Stock Titan

Click here to get full coverage on Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously - Stock Titan

Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously  Stock Titan

Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously - Stock Titan

Click here to get full coverage on BriaCell Stock Plunge: Is a Comeback Possible? - StocksToTrade

BriaCell Stock Plunge: Is a Comeback Possible?  StocksToTrade

BriaCell Stock Plunge: Is a Comeback Possible? - StocksToTrade

Click here to get full coverage on $2M Federal Cancer Grant: BriaCell's Personalized Immunotherapy Targets Metastatic Prostate Cancer Trial - Stock Titan

$2M Federal Cancer Grant: BriaCell's Personalized Immunotherapy Targets Metastatic Prostate Cancer Trial  Stock Titan

$2M Federal Cancer Grant: BriaCell's Personalized Immunotherapy Targets Metastatic Prostate Cancer Trial - Stock Titan

Click here to get full coverage on Clinical Trial: New Breast Cancer Drug Shows 17.3-Month Survival Rate, Beating Current Standard of Care - Stock Titan

Clinical Trial: New Breast Cancer Drug Shows 17.3-Month Survival Rate, Beating Current Standard of Care  Stock Titan

Clinical Trial: New Breast Cancer Drug Shows 17.3-Month Survival Rate, Beating Current Standard of Care - Stock Titan

Click here to get full coverage on BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 - GlobeNewswire

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025  GlobeNewswire

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 - GlobeNewswire

Click here to get full coverage on BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development - GuruFocus

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development  GuruFocus

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development - GuruFocus

Click here to get full coverage on BriaCell to Present Bria-OTS+ Preclinical Data at SITC 2025 Annual Meeting - Investing News Network

BriaCell to Present Bria-OTS+ Preclinical Data at SITC 2025 Annual Meeting  Investing News Network

BriaCell to Present Bria-OTS+ Preclinical Data at SITC 2025 Annual Meeting - Investing News Network

Click here to get full coverage on Here's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation - Yahoo Finance

Here's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation  Yahoo Finance

Here's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025 - GlobeNewswire

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025  GlobeNewswire

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025 - GlobeNewswire

Click here to get full coverage on BriaCell Therapeutics stock tumbles after announcing public offering - Investing.com

BriaCell Therapeutics stock tumbles after announcing public offering  Investing.com

BriaCell Therapeutics stock tumbles after announcing public offering - Investing.com

Click here to get full coverage on BCTX Stock Surge: What’s Next? - timothysykes.com

BCTX Stock Surge: What’s Next?  timothysykes.com

BCTX Stock Surge: What’s Next? - timothysykes.com

Click here to get full coverage on BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - Stocktwits

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone  Stocktwits

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - Stocktwits

Click here to get full coverage on BCTX - Briacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

BCTX - Briacell Therapeutics Corp Latest Stock News & Market Updates  Stock Titan

BCTX - Briacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on BriaCell Therapeutics Announces Closing of $15 million Public Offering - Yahoo Finance

BriaCell Therapeutics Announces Closing of $15 million Public Offering  Yahoo Finance

BriaCell Therapeutics Announces Closing of $15 million Public Offering - Yahoo Finance

Click here to get full coverage on Top 3 Earnings Acceleration Buys for November - Zacks Investment Research

Top 3 Earnings Acceleration Buys for November  Zacks Investment Research

Top 3 Earnings Acceleration Buys for November - Zacks Investment Research

Click here to get full coverage on BriaCell’s Unexpected Stock Rally: Buy or Hold? - timothysykes.com

BriaCell’s Unexpected Stock Rally: Buy or Hold?  timothysykes.com

BriaCell’s Unexpected Stock Rally: Buy or Hold? - timothysykes.com

Click here to get full coverage on Is BriaCell’s Recent Surge Valued Correctly? - StocksToTrade

Is BriaCell’s Recent Surge Valued Correctly?  StocksToTrade

Is BriaCell’s Recent Surge Valued Correctly? - StocksToTrade

Click here to get full coverage on Briacell stock maintains Buy rating at H.C. Wainwright on strong survival data - Investing.com

Briacell stock maintains Buy rating at H.C. Wainwright on strong survival data  Investing.com

Briacell stock maintains Buy rating at H.C. Wainwright on strong survival data - Investing.com

Click here to get full coverage on BriaCell Announces Proposed Effective Date of Share Consolidatio - GuruFocus

BriaCell Announces Proposed Effective Date of Share Consolidatio  GuruFocus

BriaCell Announces Proposed Effective Date of Share Consolidatio - GuruFocus

Click here to get full coverage on BriaCell Therapeutics Announces Pricing of $15 million Public Offering - GlobeNewswire

BriaCell Therapeutics Announces Pricing of $15 million Public Offering  GlobeNewswire

BriaCell Therapeutics Announces Pricing of $15 million Public Offering - GlobeNewswire

Click here to get full coverage on Biotechs on the Brink: 2 Stocks With Huge Potential - MarketBeat

Biotechs on the Brink: 2 Stocks With Huge Potential  MarketBeat

Biotechs on the Brink: 2 Stocks With Huge Potential - MarketBeat

Click here to get full coverage on BriaCell’s phase 3 breast cancer study continues after safety review - Investing.com

BriaCell’s phase 3 breast cancer study continues after safety review  Investing.com

BriaCell’s phase 3 breast cancer study continues after safety review - Investing.com

Click here to get full coverage on BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer - Yahoo Finance

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer  Yahoo Finance

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer - Yahoo Finance

Click here to get full coverage on BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now  Yahoo Finance

BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Click here to get full coverage on BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal - GlobeNewswire

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal  GlobeNewswire

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal - GlobeNewswire

Click here to get full coverage on BriaCell's Major Stock Transformation: 44M Shares Become 2.9M in Critical Nasdaq Move - Stock Titan

BriaCell's Major Stock Transformation: 44M Shares Become 2.9M in Critical Nasdaq Move  Stock Titan

BriaCell's Major Stock Transformation: 44M Shares Become 2.9M in Critical Nasdaq Move - Stock Titan

Click here to get full coverage on BriaCell Unveils Promising Clinical Data at 2025 SABCS - The Globe and Mail

BriaCell Unveils Promising Clinical Data at 2025 SABCS  The Globe and Mail

BriaCell Unveils Promising Clinical Data at 2025 SABCS - The Globe and Mail

Click here to get full coverage on What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock - Yahoo Finance

What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock  Yahoo Finance

What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock - Yahoo Finance

Click here to get full coverage on BCTX stock touches 52-week low at $0.52 amid sharp yearly decline - Investing.com

BCTX stock touches 52-week low at $0.52 amid sharp yearly decline  Investing.com

BCTX stock touches 52-week low at $0.52 amid sharp yearly decline - Investing.com

Click here to get full coverage on BriaCell stock dips on data for breast cancer drug (NASDAQ:BCTX) - Seeking Alpha

BriaCell stock dips on data for breast cancer drug (NASDAQ:BCTX)  Seeking Alpha

BriaCell stock dips on data for breast cancer drug (NASDAQ:BCTX) - Seeking Alpha

Click here to get full coverage on BriaCell receives Nasdaq non-compliance notice - Investing.com

BriaCell receives Nasdaq non-compliance notice  Investing.com

BriaCell receives Nasdaq non-compliance notice - Investing.com

Click here to get full coverage on BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns - Seeking Alpha

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns  Seeking Alpha

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns - Seeking Alpha

Click here to get full coverage on Another 100%+ One-Day Winner From My Watchlist - StocksToTrade

Another 100%+ One-Day Winner From My Watchlist  StocksToTrade

Another 100%+ One-Day Winner From My Watchlist - StocksToTrade

Click here to get full coverage on Get Rich Quick With These 3 Penny Stocks to Buy Now - InvestorPlace

Get Rich Quick With These 3 Penny Stocks to Buy Now  InvestorPlace

Get Rich Quick With These 3 Penny Stocks to Buy Now - InvestorPlace

Click here to get full coverage on BriaCell director Marc Lustig buys $2m in company shares - Investing.com

BriaCell director Marc Lustig buys $2m in company shares  Investing.com

BriaCell director Marc Lustig buys $2m in company shares - Investing.com

Click here to get full coverage on BriaCell Therapeutics: Poised To Move To Advanced Trials, But An Unconvincing Thesis - Seeking Alpha

BriaCell Therapeutics: Poised To Move To Advanced Trials, But An Unconvincing Thesis  Seeking Alpha

BriaCell Therapeutics: Poised To Move To Advanced Trials, But An Unconvincing Thesis - Seeking Alpha

Click here to get full coverage on BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics to Existing Shareholders - Investing News Network

BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics to Existing Shareholders  Investing News Network

BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics to Existing Shareholders - Investing News Network

Click here to get full coverage on There's Still Time to Buy BriaCell Therapeutics (BCTX) Stock - Market Realist

There's Still Time to Buy BriaCell Therapeutics (BCTX) Stock  Market Realist

BCTX

Price Chart

Key Statistics

Technicals

About BCTX

Latest News

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposiu - GuruFocus

BriaCell (NASDAQ: BCTX) and Receptor.AI launch AI-driven kinase inhibitor collaboration - Stock Titan

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers